VEGFR-2-IN-24

Cat. No.:	HY-147902
CAS No.:	2455414-26-1
Molecular Formula:	$C_{28}H_{23}N_3O_6S$
Molecular Weight:	529.56
Target:	VEGFR
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	VEGFR-2-IN-24 is a potent VEGFR-2 inhibitor with IC_{50} value of 0.22 μM. VEGFR-2-IN-24 can be used for tumor research[1].
IC_{50} & Target	VEGFR2 0.22 μM (IC_{50})
In Vitro	VEGFR-2-IN-24 (Compound 8f) (0-1000 μM, 72 hours; human tumor cell lines) exerts the most potent antitumor activities against human cancer cell lines[1]. VEGFR-2-IN-24 (Compound 8f) (0-1000 μM, 72 hours; human tumor cell lines) displays the highest anticancer activities with IC_{50} values of 11.19, 8.99 and 7.10 μM for HepG2, HCT-116 and MCF-7 cell lines, respectively[1]. VEGFR-2-IN-24 (Compound 8f) (0-300 μg/mL, 5 min) remarkably exhibits VEGFR-2 inhibition with IC_{50} value of 0.22 μM[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[1]

Cell Line:	Hepatocellular carcinoma (HepG2), breast cancer (MCF-7) and colorectal carcinoma (HCT-116).
Concentration:	0.1, 10, 100 and 1000 μM
Incubation Time:	72 hours
Result:	Inhibited with IC_{50} values of 11.19, 8.99 and 7.10 μM for HePG-2, MCF-7 and HCT-116, respectively.

REFERENCES

[1]. El-Adl K, et al. Design, synthesis, molecular docking and anticancer evaluations of 5-benzylidenethiazolidine-2,4-dione derivatives targeting VEGFR-2 enzyme. Bioorg Chem. 2020 Sep;102:104059.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA